An open-label, investigator-sponsored, Phase 2 study of ISIS-TTRRx in patients with transthyretin amyloid-related cardiomyopathy which includes patients with familial amyloid cardiomyopathy (FAC) and patients with wild-type transthyretin (wt-TTR) amyloidosis
Latest Information Update: 06 Jul 2020
At a glance
- Drugs Inotersen (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Therapeutic Use
- 26 May 2020 Results (N267), pooled analysis of 5 studies (NEURO-TTR, OLE, EAP, ATU, and IST) assessing outcomes of enhanced monitoring for thrombocytopenia in patients receiving inotersen presented at the 6th Congress of the European Academy of Neurology
- 26 Mar 2018 According to the Ionis Pharmaceuticals media release, new data from this study will be presented at the 16th International Symposium on Amyloidosis (ISA) 2018.
- 26 Mar 2018 Results presented in the Ionis Pharmaceuticals media release.